摘要
目的:观察思美泰治疗胆汁淤积性病毒性肝炎的疗效。方法:110例肝内胆汁淤积性病毒性肝炎患者随机分为A(治疗组)、B(对照组)两组,分别用思美泰和门冬氨酸钾镁治疗,疗程均为4周。结果:思美泰对淤胆型肝炎皮肤瘙庠的有效率为86.67%(13/15),与对照组比差异有显著性P<0.05;对慢性肝炎合并肝内胆汁淤积患者皮肤瘙痒、纳差的有效率分别为88.24%(15/17)、82.35%(14/17),与对照组比差异有显著意义P<0.05;思美泰治疗后,淤胆型肝炎和急、慢性肝炎合并肝内胆汁淤积患者血清总胆红素(STB)、血清结合胆红素(SCB)、ALT、AST的降幅明显高于对照组P<0.05;治疗后ALP的下降有显著性意义P<0.05,STB、SCB的复常率显著高于对照组P<0.05;淤胆型肝炎和慢性肝炎合并肝内胆汁淤积患者ALT的复常率较对照组差异有显著意义P<0.05;慢性肝炎合并肝内胆汁淤积患者血清白蛋白在治疗后的增高也有显著性意义P<0.05。结论:思美泰治疗胆汁淤积性病毒性肝炎疗效较好,优于门冬氨酸钾镁,没有明显不良反应。
Objective ：To observe the cholestasis - virus hepatitis therapeutic effect of Transmetil. Meth- od：110 cases of intrahepatic cholestasis -virus hepatitis patients divided into A group（ therapy group ） and B group （ control group）, A group treat with Transmetil and B group treat with potassium aspartate and mag- neium aspartate injection, the course of treatment are 4 weeks. Restflt： Compare with control group the thera- py effective power of Transmetil for the dermatopruritus is 86.67% （13/15 ） ,and has significance difference P 〈 0.05 ; Dermatopruritus or low appetite of chronic hepatitis complic intrahepatic cholestasis patients the therapy effective power is 88.24% （ 15/17 ） and 82.35% （ 14/17 ） ,compare with the control has significance difference P 〈 0.05 ;After treated by Transmetil, the degression amplitude of serum total bilirubin（ STB） ,ser- um conjugated bilirubin （ SCB ）, ALT and AST, compare with CG, have significance difference P 〈 0.05 ; Af- ter post - treatment degression amplitude of ALP has significance difference P 〈 0.05 ; STB,SCB recover rate have significance difference compare to control groupP 〈 0.05 ; The recover rate of ALT of patient with choles- tatic hepatitis or chronic hepatitis complic intrahepatic cholestasis has significance difference P 〈 0.05. The accrescence rate of SAB of the patient with chronic hepatitis complic intrahepatic cholestasis has significance difference P 〈 0.05. Conclusion： The cholestasis - viral hepatitis therapeutic effect of Transmetil is better than potassium aspartate and magneium aspartate and has less adverse reaction.
出处
《河北医学》
CAS
2007年第4期406-409,共4页
Hebei Medicine
